WordNet

travel or traverse (a distance); "This car does 150 miles per hour"; "We did 6 miles on our hike every day"
the syllable naming the first (tonic) note of any major scale in solmization (同)doh, ut
proceed or get along; "How is she doing in her new job?"; "How are you making out in graduate school?"; "Hes come a long way" (同)fare, make_out, come, get along
create or design, often in a certain way; "Do my room in blue"; "I did this piece in wood to express my love for the forest" (同)make
carry on or function; "We could do with a little more help around here" (同)manage
get (something) done; "I did my job" (同)perform
a result; "this situation developed in response to events in Africa"
a phrase recited or sung by the congregation following a versicle by the priest or minister
the manner in which an electrical or mechanical device responds to an input signal or a range of input signals
treat with an agent; add (an agent) to; "The ray dosed the paint"
the quantity of an active agent (substance or radiation) taken in or absorbed at any one time (同)dosage
a measured portion of medicine taken at any one time (同)dosage
a British imperial capacity measure (liquid or dry) equal to 1/60th fluid dram or 0.059194 cubic centimeters
a United States liquid unit equal to 1/60 fluidram
the least possible; "needed to enforce minimal standards"; "her grades were minimal"; "minimum wage"; "a minimal charge for the service" (同)minimum

PrepTutorEJDIC

《疑問文・否定文を作る》 / 《否定命令文を作る》 / 《助動詞とbe動詞のどちらも含まない文に用いて付加疑問を作る》 / 《強意語として》 / 《文》《助動詞とbe動詞のどちらも含まない文に用いて倒置文を作る》 / 《あいづちを打つ場合に》 / 《先行する動詞またはそれを含む述部の代用》 / 《so,nor,neitherで始まる簡略文で》 / …‘を'『する』,行う,果たす / 《通例have done,時にbe doneの形で》…‘を'『終える』,済ませる / …‘を'作る,作り出す / …‘を'『処理する』,整える,片付ける / 〈学課〉‘を'『勉強する』,専攻する / 〈利益・害など〉‘を'与える,もたらす / 〈人〉‘に'『役立つ』,用が足りる(serve) / …の速度で進む,距離を行く / …‘を'見物する / 〈劇〉‘を'上演する;…‘の'役を演じる / …の役目(仕事)をする / 《おもに英》…‘を'だます,かつぐ / 《話》…をへとへとにさせる / 『する』;活動する / 《通例have done,時にbe doneの形で》(…を)『終える』,済ます《+『with』+『名』》 / 〈事が〉『運ぶ』;〈人が〉暮らしていく,健康である / 〈物が〉(…に)『間に合う』,十分である;〈人が〉(…に)役に立つ,向く《+『for』+『名』》 / 《複数形で》すべきこと / 〈C〉《おもに英》大宴会,大パーティー / 〈C〉《英話》詐欺,ぺてん
ド(全音階の第1音)
〈C〉(…に対する)『返事』,『返答』《+『to』+『名』》 / 〈C〉〈U〉(…に対する)『反応』,『反響』《『to』+『名』》 / 〈C〉応答歌,応唱(牧師にならって合唱隊・会衆が短い祈り・歌を応答すること)
(おもに飲み薬1回分の)『服用量』 / (痛いこと・いやなことの)1回分,一定量 / (人などが受ける放射線の)線量 / 性病 / (…を)…‘に'投薬する,服用させる《+『名』+『with』+『名』》
ミニム(液量の最小単位) / 《英》二分音符(《米》half note)
最小の,極小の,最近の

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における微小変化群の病因、臨床的特徴、および診断 etiology clinical features and diagnosis of minimal change disease in adults
2. 成人における微小変化群の治療 treatment of minimal change disease in adults
3. 全身治療および非外科的局所治療を受けている肝細胞癌患者における治療効果判定 assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer
4. 慢性C型肝炎ウイルス感染のマネージメントの概要 overview of the management of chronic hepatitis c virus infection
5. 慢性リンパ性白血病の治療による奏効の評価 evaluating response to treatment of chronic lymphocytic leukemia

English Journal

Ovarian cancer: a brief historical overview of intraperitoneal trials.

Kwa M1, Muggia F.Author information 1NYU Cancer Institute, New York University Medical Center, New York, NY, USA.AbstractThe standard platinum-based treatment of previously untreated advanced ovarian cancer continues to evolve because despite high response rates to such first-line treatment, a majority of patients will experience relapse. For many years, the optimal treatment for women with advanced ovarian cancer has been maximum cytoreductive surgery followed by intravenous (IV) platinum and taxane chemotherapy. Later, several randomized multicenter phase III clinical trials demonstrated that intraperitoneal (IP) chemotherapy was superior to standard IV chemotherapy when there was minimal residual disease after primary debulking surgery. The underlying rationale for use of IP therapy is based on the dose-effect relationship for platinum drugs in ovarian cancer. However, barriers to implementation of IP therapy in the routine clinical setting include concern for toxicity, tolerability of planned treatment, and catheter-related complications. In this article, we highlight the key trials and recent directions in IP therapy of ovarian cancer and briefly discuss another approach to the delivery of IP chemotherapy, known as hyperthermic intraperitoneal chemotherapy.
Annals of surgical oncology.Ann Surg Oncol.2014 May;21(5):1429-34. doi: 10.1245/s10434-013-3219-8. Epub 2013 Oct 1.
The standard platinum-based treatment of previously untreated advanced ovarian cancer continues to evolve because despite high response rates to such first-line treatment, a majority of patients will experience relapse. For many years, the optimal treatment for women with advanced ovarian cancer has
PMID 24081795

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors: The First US Phase 2 Experience.

Delpassand ES1, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O'Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A.Author information 1From the *Excel Diagnostics and Nuclear Oncology Center, Houston, TX; †RadioMedix, Inc, Houston, TX; ‡Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA; §Physics Services Inc, Metairie, LA; ∥BioSynthema Inc, St Louis, MO; ¶Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Health Care, Iowa City, IA; #Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL; **IsoTherapeutics Group, Angleton, TX; ††Certus International, Inc, St Louis, MO; ‡‡Iso-Tex Diagnostics, Inc, Friendswood, TX; and §§Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.AbstractOBJECTIVE: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs is a novel method of treatment in patients with metastatic neuroendocrine tumors (NETs). For the first time in the United States, we present preliminary results of the treatment with Lutetium 177 (Lu) DOTATATE in patients with progressive NETs.
Pancreas.Pancreas.2014 May;43(4):518-25. doi: 10.1097/MPA.0000000000000113.
OBJECTIVE: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs is a novel method of treatment in patients with metastatic neuroendocrine tumors (NETs). For the first time in the United States, we present preliminary results of the treatment with Lutetium 177 (Lu) DOTATATE in
PMID 24632546

Oral arsenic trioxide based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.

Gill H1, Au WY, Cheung WW, Lee EY, Kwong YL.Author information 1Department of Medicine, Queen Mary Hospital, Hong Kong.AbstractBACKGROUND: Mantle cell lymphoma (MCL) is aggressive, and relapsed/refractory disease has poor outcomes.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.Ann Oncol.2014 Apr 12. [Epub ahead of print]
BACKGROUND: Mantle cell lymphoma (MCL) is aggressive, and relapsed/refractory disease has poor outcomes.PATIENTS AND METHODS: Thirty-nine patients (men=34, women=5) at 64 (41-82) years of age with relapsed/refractory MCL, ineligible for high-dose chemotherapy and had received 2 (1-5) prior regimens,
PMID 24728036